Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

Part of paid clinical trials in Aurora, Colorado.

Sponsor
AstraZeneca
Study ID
NCT02588105
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Solid Tumours

Eligibility Criteria

Sex
ALL
Age
18 Years - 130 Years
Healthy Volunteers
Not accepted

Interventions

  • AZD0156 — DRUG
    All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.
  • Olaparib — DRUG
    Module 1 combination with olaparib
  • irinotecan — DRUG
    Module 2 combination with irinotecan/FOLFIRI
  • Fluorouracil — DRUG
    Module 2 combination with irinotecan/FOLFIRI
  • Folinic Acid — DRUG
    Module 2 combination with irinotecan/FOLFIRI

Study Details

The purpose of this study is to determine whether AZD0156 is safe, what is the best dose to give, and how it is processed by the body when given alone or in combination with other agents. The study will also collect some initial information about how effective it is.

Key Dates

Start date
Nov 10, 2015
Status verified
Sep 2022
Primary completion
Sep 13, 2019
Completion
Jul 26, 2022

Study Design

Enrollment
84 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Safety and Tolerability
    All patients will receive AZD0156 as a monotherapy or in combination with either olaparib, cytotoxic chemotherapies, or novel anti-cancer agents to assess safety and tolerability

Primary Outcome Measure

Safety and tolerability - Number of patients experiencing adverse events [ Time Frame: Informed consent until end of Safety Follow-up (approximately 6 months) ]

Locations (2)

FacilityCityStateZIPSite coordinators
Research SiteAuroraColorado80045-
Research SiteNew YorkNew York10033-

Find similar trials in Aurora, CO

By research site
Research Site· Aurora, COResearch Site· New York, NY

Related Studies